Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Given Consensus Rating of “Moderate Buy” by Brokerages

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.00.

WHWK has been the subject of several research analyst reports. Oppenheimer reissued an “outperform” rating and set a $7.00 price objective on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Citigroup initiated coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating for the company. Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Citizens Jmp initiated coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price objective for the company. Finally, Weiss Ratings lowered Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th.

Insider Activity at Whitehawk Therapeutics

In related news, CEO David James Lennon sold 14,500 shares of Whitehawk Therapeutics stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $3.38, for a total transaction of $49,010.00. Following the completion of the sale, the chief executive officer owned 518,622 shares of the company’s stock, valued at approximately $1,752,942.36. This trade represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Scott M. Giacobello sold 141,600 shares of Whitehawk Therapeutics stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $4.13, for a total value of $584,808.00. Following the sale, the chief financial officer directly owned 295,224 shares of the company’s stock, valued at $1,219,275.12. This represents a 32.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 695,830 shares of company stock valued at $2,553,026. Company insiders own 49.90% of the company’s stock.

Institutional Investors Weigh In On Whitehawk Therapeutics

Several hedge funds have recently added to or reduced their stakes in WHWK. Vanguard Group Inc. bought a new stake in Whitehawk Therapeutics during the third quarter worth about $2,552,000. Dimensional Fund Advisors LP bought a new stake in Whitehawk Therapeutics during the third quarter worth about $84,000. Avoro Capital Advisors LLC bought a new stake in Whitehawk Therapeutics during the third quarter worth about $5,414,000. Suvretta Capital Management LLC bought a new stake in Whitehawk Therapeutics during the third quarter worth about $7,030,000. Finally, Squarepoint Ops LLC bought a new stake in Whitehawk Therapeutics during the third quarter worth about $159,000. Institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Price Performance

Whitehawk Therapeutics stock opened at $4.41 on Tuesday. Whitehawk Therapeutics has a one year low of $1.57 and a one year high of $5.49. The business has a fifty day moving average price of $4.28 and a 200-day moving average price of $3.50. The firm has a market capitalization of $218.07 million, a P/E ratio of -2.63 and a beta of 0.77.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. Sell-side analysts expect that Whitehawk Therapeutics will post -1.37 earnings per share for the current fiscal year.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.